Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hepatitis B surface antigen + monophosphoryl lipid A + aluminum salts
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
A combination vaccine formulation containing recombinant hepatitis B surface antigen (HBsAg) as the immunogen, with monophosphoryl lipid A (MPL) and aluminum salts as adjuvants. MPL is a detoxified derivative of lipopolysaccharide from bacterial cell walls that stimulates innate immunity, while aluminum salts enhance the immune response by promoting antigen uptake and presentation. This adjuvant system has been shown to increase both humoral and cellular immune responses compared to traditional alum-only vaccines, leading to more rapid and robust protection against hepatitis B infection. The combination has demonstrated safety, tolerability, and enhanced immunogenicity in clinical studies[4][7]. The primary indication is prevention of hepatitis B virus infection.
- Other names
- HBsAg + MPL + aluminium salts
02
Targets
CD14 (Monocyte differentiation antigen CD14)MYD88 (Myeloid differentiation primary response protein MyD88)TIRAP (TIRAP / MAL)TRIF (TIR-domain-containing adapter-inducing interferon-beta)HBsAg (Hepatitis B surface antigen)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Hepatitis B surface antigen + monophosphoryl lipid A + aluminum salts.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepatitis B surface antigen + monophosphoryl lipid A + aluminum salts.